Barriers and facilitators to conduct high-quality, large-scale safety and comparative effectiveness research: The Biologics and Biosimilars Collective Intelligence Consortium experience.

Lockhart, Catherine M; McDermott, Cara L; Felix, Thomas; Lin, Nancy D; Cziraky, Mark J; Mendelsohn, Aaron B; Brown, Jeffrey S

Lockhart, Catherine M; McDermott, Cara L; Felix, Thomas; Lin, Nancy D; Cziraky, Mark J; Mendelsohn, Aaron B; Brown, Jeffrey S.

Afiliação

Lockhart CM; Biologics and Biosimilars Collective Intelligence Consortium, Academy of Managed Care Pharmacy, Alexandria, VA, USA.
McDermott CL; Biologics and Biosimilars Collective Intelligence Consortium, Academy of Managed Care Pharmacy, Alexandria, VA, USA.
Felix T; Intercontinental Medical Affairs, Amgen, Thousand Oaks, CA, USA.
Lin ND; Epidemiology, OptumInsight Inc, Eden Prairie, MN, USA.
Cziraky MJ; Research Development and Operations, HealthCore, Wilmington, DE, USA.
Mendelsohn AB; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA.
Brown JS; Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA.

Pharmacoepidemiol Drug Saf ; 29(7): 811-813, 2020 07.

Article em En | MEDLINE | ID: mdl-31402533

Assuntos

Medicamentos Biossimilares; Pesquisa Comparativa da Efetividade; Humanos; Projetos de Pesquisa

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pesquisa Comparativa da Efetividade / Medicamentos Biossimilares Tipo de estudo: Guideline Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google